GMT Capital Corp Decreases Stock Position in OptiNose, Inc. (NASDAQ:OPTN)

GMT Capital Corp reduced its position in OptiNose, Inc. (NASDAQ:OPTN - Free Report) by 93.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,047 shares of the company's stock after selling 1,036,655 shares during the period. GMT Capital Corp owned approximately 0.74% of OptiNose worth $495,000 at the end of the most recent quarter.

Separately, State Street Corp boosted its holdings in OptiNose by 14.2% in the third quarter. State Street Corp now owns 341,303 shares of the company's stock valued at $229,000 after purchasing an additional 42,500 shares during the last quarter. Institutional investors own 85.60% of the company's stock.

OptiNose Stock Up 0.1 %

Shares of NASDAQ OPTN opened at $9.17 on Wednesday. The stock's 50 day moving average price is $7.45 and its two-hundred day moving average price is $7.65. OptiNose, Inc. has a 52-week low of $4.82 and a 52-week high of $20.03. The stock has a market capitalization of $92.36 million, a P/E ratio of -2.18 and a beta of -0.87.

OptiNose (NASDAQ:OPTN - Get Free Report) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.67. The firm had revenue of $21.47 million for the quarter, compared to analyst estimates of $21.02 million. On average, analysts anticipate that OptiNose, Inc. will post -3.22 EPS for the current year.

Analysts Set New Price Targets

OPTN has been the topic of several analyst reports. Piper Sandler restated a "neutral" rating and set a $9.00 price objective (down from $15.00) on shares of OptiNose in a report on Friday, March 21st. HC Wainwright restated a "neutral" rating and issued a $9.00 price target (down previously from $18.00) on shares of OptiNose in a research note on Friday, March 21st. Finally, Lake Street Capital downgraded shares of OptiNose from a "buy" rating to a "hold" rating and reduced their price objective for the company from $17.00 to $9.00 in a research note on Thursday, March 20th.

Insider Activity

In other OptiNose news, CEO Ramy A. Mahmoud sold 6,376 shares of the firm's stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.29, for a total value of $33,729.04. Following the transaction, the chief executive officer now owns 126,931 shares of the company's stock, valued at $671,464.99. This trade represents a 4.78 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders sold 8,213 shares of company stock valued at $43,643. Company insiders own 2.30% of the company's stock.

OptiNose Profile

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.